Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases

In Soo Kim; Prashanta Silwal; Eun-Kyeong Jo

doi:10.3390/cells12040650

Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases

Cells. 2023 Feb 17;12(4):650. doi: 10.3390/cells12040650.

Authors

In Soo Kim^{1

2

3}, Prashanta Silwal⁴, Eun-Kyeong Jo^{1

2

3}

Affiliations

¹ Department of Microbiology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
² Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
³ Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
⁴ Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.

Abstract

Peroxisome proliferator-activated receptors (PPARs) α, β, and γ are nuclear receptors that orchestrate the transcriptional regulation of genes involved in a variety of biological responses, such as energy metabolism and homeostasis, regulation of inflammation, cellular development, and differentiation. The many roles played by the PPAR signaling pathways indicate that PPARs may be useful targets for various human diseases, including metabolic and inflammatory conditions and tumors. Accumulating evidence suggests that each PPAR plays prominent but different roles in viral, bacterial, and parasitic infectious disease development. In this review, we discuss recent PPAR research works that are focused on how PPARs control various infections and immune responses. In addition, we describe the current and potential therapeutic uses of PPAR agonists/antagonists in the context of infectious diseases. A more comprehensive understanding of the roles played by PPARs in terms of host-pathogen interactions will yield potential adjunctive personalized therapies employing PPAR-modulating agents.

Keywords: bacteria; infection; parasite; peroxisome proliferator-activated receptor; virus.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Communicable Diseases*
Gene Expression Regulation
Humans
Inflammation
PPAR alpha
Receptors, Cytoplasmic and Nuclear*

Substances

Receptors, Cytoplasmic and Nuclear
PPAR alpha

Grants and funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (grant number: 2017R1A5A2015385). Additionally, this research was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI22C1361).